From the most recent 8K: “In the next two months, we expect data from five clinical studies to be presented at major medical meetings — the results from the T-DM1 Phase II study that could support a registration filing in 2010 if the findings are compell
http://phx.corporate-ir.net/phoenix.zhtm...

Excerpt:

"Clinical findings from the trastuzumab-DM1 (T-DM1) Phase II trial have been accepted for presentation at the San Antonio Breast Cancer Symposium in December 2009. Roche has indicated that, if compelling, these data could enable a T-DM1 marketing application to be filed in 2010.
..............................................
T-dm1 clinical trials listing: http://www.clinicaltrials.gov/ct2/result...
s=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e=
......................................................................

· Clinical findings with IMGN901 in the treatment of solid tumors have been accepted for presentation at the AACR-NCI-EORTC conference in November 2009, and clinical data with IMGN901, SAR3419 and BT-062 in the treatment of liquid tumors have been accepted for presentation at the American Society of Hematology meeting in December 2009.

..........
· The first preclinical findings with the Company’s second family of payload agents — the IGNs — will be presented at the AACR-NCI-EORTC conference in November."
--------------------------------------------------------------

FIRST CONFERENCE:
http://www.aacr.org/home/scientists/meet...

SECOND CONFERENCE:
http://www.hematology.org/Meetings/Annua...

THIRD CONFERENCE:
http://www.sabcs.org/
We should hear something soon on IMGN901.

First a bit about multiple melanoma:

https://health.google.com/health/ref/Mul...

"Treatment
The goal of treatment is to relieve symptoms.
People who have mild disease or a questionable diagnosis are usually carefully monitored without treatment. Some people have a slow-developing form of multiple myeloma that takes years to cause symptoms.
Treatment begins when the disease becomes worse or causes symptoms.
Chemotherapy and radiation therapy may be performed to relieve bone pain or treat a bone tumor.
Bone marrow transplantation in younger patients has been shown to increase disease-free and overall survival, but it has significant risks.
Medications for multiple myeloma include decadron, melophalan, thalidomide, lenalidomide (Revlimid), and bortezomib (Velcade). Bisphosphonates are used to prevent fractures.
People with multiple myeloma should drink plenty of fluids to prevent dehydration and help maintain proper kidney function. They should also be cautious when having x-ray tests that use contrast dye.


Chemotherapy and transplants rarely lead to a permanent cure."

AND:

http://informahealthcare.com/doi/abs/10....
Excerpt: "CD56 is a neural adhesion molecule and expressed in 70–80% cases of multiple myeloma (MM)."


3 clinical trials for IMGN901 for multiple melanoma:

http://clinicaltrials.gov/ct2/results?te...
&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e=

This one is I think the one we should hear about soon as it is supposed to begin in December 2009. Will efficacy results be good and be presented prior to the start of the study?

http://clinicaltrials.gov/ct2/show/NCT00...


ALSO upcoming - 2 clinical trials for BT062

http://clinicaltrials.gov/ct2/results?te...
d=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&lo cn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e=